What to Do If Your Cholesterol Levels Are Too High

When laboratory testing reveals elevated cholesterol levels—particularly high low-density lipoprotein (LDL) cholesterol or total cholesterol—clinicians refer to this as hypercholesterolemia. This condition significantly increases the risk of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke, due to progressive plaque buildup in arterial walls.

Management begins with a comprehensive cardiovascular risk assessment, incorporating factors such as age, sex, blood pressure, smoking status, diabetes mellitus, family history of premature coronary artery disease, and results from lipid panels—including LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, and non-HDL cholesterol. Risk calculators like the ASCVD Risk Estimator Plus may guide treatment intensity decisions.

First-line intervention is intensive lifestyle modification: adoption of a heart-healthy dietary pattern rich in whole grains, legumes, nuts, fruits, vegetables, and fatty fish; reduction of saturated fats (e.g., red meat, full-fat dairy) and elimination of industrially produced trans fats; achievement and maintenance of healthy body weight; and engagement in at least 150 minutes per week of moderate-intensity aerobic activity.

For individuals at elevated or high ASCVD risk—or those with established cardiovascular disease, diabetes, or severe primary hypercholesterolemia—guideline-directed pharmacotherapy is indicated. High-intensity statins (e.g., atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) are first-line agents, proven to reduce major adverse cardiovascular events by lowering LDL-C by ≥50%. If target LDL-C goals are not achieved, combination therapy—such as adding ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor—may be considered.

Regular follow-up is essential: lipid panels should be repeated 4–12 weeks after initiating or adjusting therapy, then every 3–12 months thereafter, depending on clinical stability and treatment response. Patient education, shared decision-making, and attention to medication adherence and tolerability—including monitoring for muscle-related symptoms or hepatic enzyme elevations—are integral components of long-term management.